{"id":"intravitreal-topotecan","safety":{"commonSideEffects":[{"rate":"null","effect":"Vision disorder"},{"rate":"null","effect":"Cytopenia"}]},"_chembl":{"chemblId":"CHEMBL84","moleculeType":"Small molecule","molecularWeight":"421.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Topotecan works by inhibiting topoisomerase I, an enzyme involved in DNA replication and transcription. This leads to DNA damage and ultimately cell death in rapidly dividing cancer cells.","oneSentence":"Topoisomerase I inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:55:42.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Retinoblastoma"},{"name":"Malignant glioma"}]},"trialDetails":[{"nctId":"NCT06425419","phase":"PHASE1","title":"The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2026-04-01","conditions":"Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy, Rhegmatogenous Retinal Detachment","enrollment":50},{"nctId":"NCT04681417","phase":"PHASE2, PHASE3","title":"Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2021-03-25","conditions":"Retinoblastoma","enrollment":225},{"nctId":"NCT06972602","phase":"EARLY_PHASE1","title":"High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-04-01","conditions":"Retinoblastoma, Retinoblastoma, Recurrent","enrollment":10},{"nctId":"NCT06818721","phase":"PHASE2","title":"Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment","status":"NOT_YET_RECRUITING","sponsor":"Unity Health Toronto","startDate":"2025-03","conditions":"Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy","enrollment":394},{"nctId":"NCT05523869","phase":"PHASE2","title":"Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2023-02-23","conditions":"Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment","enrollment":50},{"nctId":"NCT04455139","phase":"PHASE2","title":"A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma","status":"TERMINATED","sponsor":"Prof. Beck Popovic Maja","startDate":"2021-11-15","conditions":"Eye Cancer, Retinoblastoma","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Topotecan"],"phase":"phase_2","status":"active","brandName":"Intravitreal topotecan","genericName":"Intravitreal topotecan","companyName":"Unity Health Toronto","companyId":"unity-health-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topoisomerase I inhibitor Used for Retinoblastoma, Malignant glioma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}